Impel Pharmaceuticals Inc.
IMPL · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $5,023 | $6,584 | $4,372 | $5,008 |
| % Growth | -23.7% | 50.6% | -12.7% | – |
| Cost of Goods Sold | $2,230 | $3,220 | $2,285 | $2,217 |
| Gross Profit | $2,793 | $3,364 | $2,087 | $2,791 |
| % Margin | 55.6% | 51.1% | 47.7% | 55.7% |
| R&D Expenses | $252 | $200 | $3,003 | $700 |
| G&A Expenses | $15,352 | $19,268 | $22,037 | $20,332 |
| SG&A Expenses | $15,352 | $19,268 | $22,037 | $20,332 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15,604 | $19,468 | $25,040 | $21,032 |
| Operating Income | -$12,811 | -$16,104 | -$22,953 | -$18,241 |
| % Margin | -255% | -244.6% | -525% | -364.2% |
| Other Income/Exp. Net | -$1,003 | $8,747 | -$5,631 | -$4,799 |
| Pre-Tax Income | -$13,814 | -$7,357 | -$30,067 | -$23,041 |
| Tax Expense | $0 | $0 | $8,564 | $13,271 |
| Net Income | -$13,814 | -$7,357 | -$38,631 | -$36,312 |
| % Margin | -275% | -111.7% | -883.6% | -725.1% |
| EPS | -0.58 | -0.31 | -1.63 | -1.53 |
| % Growth | -87.1% | 81% | -6.5% | – |
| EPS Diluted | -0.58 | -0.31 | -1.63 | -1.53 |
| Weighted Avg Shares Out | 23,749 | 23,732 | 23,675 | 23,739 |
| Weighted Avg Shares Out Dil | 23,749 | 23,748 | 23,746 | 23,739 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $2,766 |
| Interest Expense | $0 | $0 | $0 | $17,027 |
| Depreciation & Amortization | $635 | -$57 | $1,483 | $306 |
| EBITDA | -$16,840 | -$16,104 | -$24,436 | -$5,709 |
| % Margin | -335.3% | -244.6% | -558.9% | -114% |